Trial Profile
A Phase I Combination Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Lodapolimab (Primary) ; Prexasertib (Primary)
- Indications Carcinoma; Colorectal cancer; Leiomyosarcoma; Ovarian cancer; Soft tissue sarcoma; Solid tumours; Uterine cancer
- Focus Adverse reactions
- 01 Oct 2021 Results assessing the immune modulating effect and safely in combination at the RP2D of CHK1 inhibition with prexasertib in combination with LY3300054, published in the Cancer Immunology Immunotherapy.
- 09 Feb 2021 Status changed from active, no longer recruiting to completed.
- 03 Feb 2020 Status changed from recruiting to active, no longer recruiting.